|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"lim h y"
Showing items 41-48 of 48 (2 Page(s) Totally)
<< < 1 2
View [10|25|50] records per page
| 國立成功大學 |
2020 |
Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
|
Yen, C.-J.;Kudo, M.;Lim, H.-Y.;Hsu, C.-H.;Vogel, A.;Brandi, G.;Cheng, R.;Nitu, I.S.;Abada, P.;Hsu, Y.;Zhu, A.X.;Kang, Y.-K. |
| 國立成功大學 |
2019 |
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Zhu, A.X.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Pracht, M.;Lim, H.Y.;Rau, K.-M.;Motomura, K.;Ohno, I.;Merle, P.;Daniele, B.;Shin, D.B.;Gerken, Gerken G.;Borg, C.;Hiriart, J.-B.;Okusaka, T.;Morimoto, Morimoto M.;Hsu, Y.;Abada, P.B.;Kudo, M.;investigators, REACH-2 study |
| 國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
| 國立成功大學 |
2018 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G.K.;Qin, S.;Ryoo, B.-Y.;Lu, S.-N.;Yen, C.-J.;Feng, Y.-H.;Lim, H.Y.;Izzo, F.;Colombo, M.;Sarker, D.;Bolondi, L.;Vaccaro, G.;Harris, W.P.;Chen, Z.;Hubner, R.A.;Meyer, T.;Sun, W.;Harding, J.J.;Hollywood, E.M.;Ma, J.;Wan, P.J.;Ly, M.;Bomalaski, J.;Johnston, A.;Lin, C.-C.;Chao, Y.;Chen, L.-T. |
| 國立成功大學 |
2018 |
Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular Carcinoma
|
Lim, H.Y.;Merle, P.;Weiss, K.H.;Yau, T.;Ross, P.;Mazzaferro, V.;Blanc, J.-F.;Ma, Y.T.;Yen, C.J.;Kocsis, J.;Choo, S.P.;Sukeepaisarnjaroen, W.;Gerolami, R.;Dufour, J.-F.;Gane, E.J.;Ryoo, B.-Y.;Peck-Radosavljevic, M.;Dao, T.;Yeo, W.;Lamlertthon, W.;Thongsawat, S.;Teufel, M.;Roth, K.;Reis, D.;Childs, B.H.;Krissel, H.;Llovet, J.M. |
| 臺大學術典藏 |
2015 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Oh D.-Y.; Chiun Hsu; Chen J.-S.; Chen L.-T.; Orlando M.; Kim J.S.; Lim H.Y.; Park J.O.; Park J.O.;Oh D.-Y.;Chiun Hsu;Chen J.-S.;Chen L.-T.;Orlando M.;Kim J.S.;Lim H.Y. |
| 國立成功大學 |
2013-06 |
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
|
Roy, A. C.; Park, S. R.; Cunningham, D.; Kang, Y. K.; Chao, Y.; Chen, L. T.; Rees, C.; Lim, H. Y.; Tabernero, J.; Ramos, F. J.; Kujundzic, M.; Cardic, M. B.; Yeh, C. G.; de Gramont, A. |
| 臺大學術典藏 |
2010 |
Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
|
Yeo W.; Chen P.-J.; Furuse J.; Han K.-H.; CHIUN HSU; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L. |
Showing items 41-48 of 48 (2 Page(s) Totally)
<< < 1 2
View [10|25|50] records per page
|
